November 7, 2024
Plus Therapeutics partners with SpectronRx for CNS therapy development
Plus Therapeutics has entered into a manufacturing services agreement (MSA) with SpectronRx to produce the radiotherapy, Rhenium (186Re) Obisbemeda, for central nervous system (CNS) cancers.